Liposarcoma Therapeutics Market to Escalate During the Forecast Period | Key Companies includes – Sanofi, Janssen, Eisai, Rain Therapeutics, Karyopharm, GlaxoSmithKline, Novartis, Incyte and Others

Liposarcoma Therapeutics Market to Escalate During the Forecast Period | Key Companies includes - Sanofi, Janssen, Eisai, Rain Therapeutics, Karyopharm, GlaxoSmithKline, Novartis, Incyte and Others

“Delveinsight Business Research LLP”
DelveInsight’s “Liposarcoma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Liposarcoma Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Liposarcoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Liposarcoma Market Analysis

Liposarcoma: An Overview

According to the National Organization of Rare Disorders (NORD), “Liposarcoma (LPS) is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as cancer (malignant) because of its potential to recur locally and spread to other areas of the body.”

The specific cause of liposarcoma is still unknown. Clinically, it can be first noticed particularly in the extremity in an area of recent trauma where the patient may find a mass, however, the cause and effect are quite likely purely coincidental. Liposarcoma generally is attributed to a change in some of the genes that are normally present in fat cells. A series of abnormalities in these genes (mutations or DNA alterations) can lead to malignant changes characterized by uncontrollable growth.

Liposarcoma Market Key Facts

  • As per NORD, Liposarcoma is a soft tissue sarcoma, affecting approximately 2000 individuals each year in the United States. The incidence is approximately 1 per 100, 000 persons/years. It affects men more than women, and more specifically middle-aged men ranging from 50–65 years of age. Children are rarely diagnosed, but when liposarcoma does occur in children, it is usually during adolescence. There is no specific ethnicity in which liposarcoma is more common.

  • Internationally, with an annual incidence of 2.5 cases per million population, liposarcoma is the most common soft tissue sarcoma, accounting for approximately 17% of all soft tissue sarcomas and 3% of all liposarcomas in the head and neck region (usually the neck and the cheek).

  • According to NORD, males are more affected with liposarcoma than females.

Key Benefits of Liposarcoma Market Report

  • The report provides an in-depth analysis of Liposarcoma Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Liposarcoma Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Liposarcoma’s current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Liposarcoma market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Liposarcoma Market

The market size of Liposarcoma is expected to increase during the forecast period owing to the extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Liposarcoma market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Liposarcoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Get FREE sample copy at:

Liposarcoma Epidemiology

The epidemiology section covers insights about the historical and current Liposarcoma patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Liposarcoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liposarcoma market or expected to get launched in the market during the study period. The analysis covers Liposarcoma market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Liposarcoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Key companies in the Liposarcoma market include:

  • Sanofi

  • Janssen

  • Eisai

  • Rain Therapeutics

  • Karyopharm Therapeutics

  • GlaxoSmithKline/Novartis

  • Incyte Corporation

  • Mirati Therapeutics

And many others.

Liposarcoma therapies covered in the report include:

  • DS-3032

  • Selinexor

  • INCMGA00012

  • Sitravatinib

  • Cabazitaxel

And many others.

Request for Sample @ Liposarcoma Therapeutics Market Assessment

Table of Content

1. Key Insights

2. Executive Summary 

3. Liposarcoma Competitive Intelligence Analysis

4. Liposarcoma Market Overview at a Glance

5. Liposarcoma Disease Background and Overview

6. Liposarcoma Patient Journey

7. Liposarcoma Epidemiology and Patient Population

8. Liposarcoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Liposarcoma Unmet Needs

10. Key Endpoints of Liposarcoma Treatment

11. Liposarcoma Marketed Products

12. Liposarcoma Emerging Therapies

13. Liposarcoma Seven Major Market Analysis

14. Attribute Analysis

15. Liposarcoma Market Outlook (7 major markets)

16. Liposarcoma Access and Reimbursement Overview

17. KOL Views on the Liposarcoma Market.

18. Liposarcoma Market Drivers

19. Liposarcoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Reports By DelveInsight

Liposarcoma Pipeline Insights
Liposarcoma Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Liposarcoma market.

Trending Healthcare Blogs –

Follicular Lymphoma Market Outlook
As per DelveInsight analysis, in 2020, the Follicular Lymphoma market revenue was estimated to be USD 1,451 million in the 7MM (i.e the USA, EU5, and Japan), which is anticipated to increase further by 2030. Among the 7MM, the USA accounted for approximately 54% of the total market share, depicting a promising future outlook. Some of the key companies in the segment diligently working to overcome the therapeutics challenges with their pipeline products include Incyte, Bristol Myers Squibb, Nordic Nanovector ASA, ADC Therapeutics, MorphoSys, Regeneron, Novartis, MEI Pharma, BeiGene, Xynomic Pharma, TG Therapeutics, Inc., Roche, Takeda, and several others. For more details, visit: Follicular Lymphoma Therapeutics Market


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States